Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

[1]  R. Jain,et al.  Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. , 1996, British Journal of Cancer.

[2]  C. Springer,et al.  Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). , 1995, Journal of medicinal chemistry.

[3]  I. Niculescu-Duvaz,et al.  Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy , 1995, Current Medicinal Chemistry.

[4]  I. Niculescu-Duvaz,et al.  Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. , 1994, Journal of medicinal chemistry.

[5]  C. Springer,et al.  Galactosylated antibodies and antibody‐enzyme conjugates in antibody‐directed enzyme prodrug therapy , 1994, Cancer.

[6]  J. Boyle,et al.  Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. , 1993, Journal of immunological methods.

[7]  K. Bagshawe,et al.  ANTIBODY-ENZYME CONJUGATES CAN GENERATE CYTOTOXIC DRUGS FROM INACTIVE PRECURSORS AT TUMOR SITES , 1991 .

[8]  C. Springer,et al.  Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). , 1991, Anti-cancer drug design.

[9]  C. Springer,et al.  Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. , 1991, European journal of cancer.

[10]  C. Springer,et al.  Antibody directed enzyme prodrug therapy (ADEPT): clinical report. , 1991, Disease markers.

[11]  R. Sherwood,et al.  Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. , 1990, British Journal of Cancer.

[12]  S. Sharma,et al.  Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. , 1990, British Journal of Cancer.

[13]  C. Springer,et al.  Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. , 1990, Journal of medicinal chemistry.

[14]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[15]  C. Springer,et al.  A cytotoxic agent can be generated selectively at cancer sites. , 1988, British Journal of Cancer.

[16]  W. Denny,et al.  ANTIBODY-DIRECTED ENZYME-PRODRUG THERAPY (ADEPT) , 1996 .

[17]  D. Kerr,et al.  Generation of cytotoxic agents by targeted enzymes. , 1993, Bioconjugate chemistry.

[18]  C. Springer,et al.  Synthesis of an N-mustard prodrug , 1990 .